文献速递肿瘤 PET/CT

进展期胃癌化疗中肿瘤大小与代谢变化的前瞻性评估:关联与临床意义

Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication.
PubMed 文献 · J Nucl Med · 2016-11-10

前瞻性纳入74例拟行一线姑息化疗的进展期胃癌患者,共620处病灶,同期用增强CT和18F-FDG PET评估肿瘤直径、SUVmax及总病灶糖酵解的变化。结果显示化疗后SUVmax变化与肿瘤大小变化呈线性相关,肿瘤缩小30%对应SUVmax下降50%(P<0.001);肿瘤大小与SUVmax同时下降者总生存和无进展生存均优于仅其一者。

要点

  • 低黏附性癌SUVmax低于腺癌,不论肿瘤大小(P<0.001);HER2阳性者SUVmax高于HER2阴性者(P=0.002)。
  • 化疗后SUVmax变化与各病灶肿瘤大小变化呈线性相关,肿瘤缩小30%对应SUVmax下降50%(P<0.001)。
  • 肿瘤大小与SUVmax同时下降者总生存(P=0.003)和无进展生存(P=0.038)优于仅其一者。

核心结论

  • 进展期胃癌化疗引起的肿瘤代谢变化与肿瘤大小变化相关,同时考虑代谢与大小变化有助于更准确预测接受化疗患者的预后。

研究设计与样本

  • 前瞻性纳入拟开始一线姑息化疗的进展期胃癌患者,基线及随访时同期行增强CT和18F-FDG PET评估。
  • 纳入CT上最大长径超过1 cm的全部病灶,每处病灶行匹配的18F-FDG PET评估。
  • 共纳入74例患者、620处病灶,分析代谢变化与肿瘤大小变化的关联,并对总生存和无进展生存进行结局分析。

主要发现

  • 低黏附性癌较腺癌SUVmax更低,不论肿瘤大小(P<0.001)。
  • HER2阳性肿瘤SUVmax高于HER2阴性肿瘤(P=0.002)。
  • 化疗所致SUVmax变化与各病灶肿瘤大小变化呈线性相关,肿瘤缩小30%对应SUVmax下降50%(P<0.001)。
  • 总病灶糖酵解变化亦与肿瘤大小变化相关(P<0.001)。
  • 肿瘤大小与SUVmax同时下降者较仅大小或仅SUVmax下降者获得更好的总生存(P=0.003)和无进展生存(P=0.038)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A change in tumor size is a well-validated and commonly used value for evaluating response to chemotherapy in cancer. Metabolic changes induced by chemotherapy are related to prognosis in several tumor types. However, the clinical implication of metabolic changes in patients with advanced gastric cancer (AGC) undergoing chemotherapy remains unclear. We aimed to evaluate response of tumor size and metabolism in AGC during chemotherapy and to reveal the relationship between them in view of their impact on patient survival. Methods: We prospectively enrolled patients with AGC before the initiation of first-line palliative chemotherapy. Using baseline and follow-up contrast-enhanced CT and 18F-FDG PET, we assessed the tumor diameter, SUVmax, and total lesion glycolysis in each lesion and their changes during chemotherapy at the same time. We included all lesions with the maximal longest diameters over 1 cm on CT, and each lesion was evaluated by matched 18F-FDG PET. We analyzed the association between changes in tumor metabolism and tumor size and performed outcome analysis on overall survival (OS) and progression-free survival (PFS). Results: Seventy-four patients were enrolled, and the number of all lesions included in this study was 620. Compared with adenocarcinomas, poorly cohesive carcinomas demonstrated lower SUVmax irrespective of tumor size (P < 0.001). Human epidermal growth factor receptor 2 (HER2)-positive tumors showed higher SUVmax than HER2-negative tumors (P = 0.002). The changes in SUVmax due to chemotherapy had a linear correlation with the changes in tumor size of each lesion, and a 30% tumor size reduction was associated with a 50% SUVmax reduction (P < 0.001). Total lesion glycolysis changes also correlated with tumor size changes (P < 0.001). Better OS and PFS were obtained in patients with both tumor size and SUVmax reduction than in patients with either size or SUVmax reduction only (OS, P = 0.003; PFS, P = 0.038). Conclusion: Changes in tumor metabolism induced by chemotherapy correlated with changes in tumor size in AGC. Considering both changes in metabolism and size could help predict a more accurate prognosis for AGC patients undergoing chemotherapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Park S, Ha S, Kwon HW, et al. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. J Nucl Med. 2016. PMID: 28572288. doi:10.2967/jnumed.116.182675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。